Amylyx Pharmaceuticals’ ALS drug is seemingly headed for a rockier path in the EU than it faced in the US and Canada.
The biotech announced Tuesday morning that the bloc’s drug review committee, known as CHMP, is expected to issue a “negative opinion” and recommend against approving the drug next month. If that negative opinion comes to pass, Amylyx expects to appeal in a…